Hughes Steven George 4

What Happened

• Steven G. Hughes, Chief Medical Officer of Atrium Therapeutics (RNA), received two awards reported on Form 4: 30,000 restricted stock units (RSUs) and 60,000 derivative awards, both recorded as acquired on 2026-04-20 at $0.00 (total cash paid = $0).
• These are grants (insider code A), not open-market purchases or sales, so there was no immediate cash outlay or sale proceeds.

Key Details

• Transaction date: 2026-04-20; Form 4 filed: 2026-04-22 (timely filing).
• Grants: 30,000 RSUs @ $0.00 (F1) and 60,000 derivative awards @ $0.00 (F2); reported value $0 for each line.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes:
  • F1: The 30,000 RSUs each convert to one share. 25% vest on March 20, 2027, then the remainder vests in three substantially equal yearly installments thereafter, subject to continuous service.
  • F2: For the 60,000 derivative award, 25% of the underlying shares vest on March 20, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to continuous service.
• Filing timeliness: filed two days after the transaction (appears timely under Form 4 rules).

Context

• These are grants/awards (not purchases or option exercises followed by sales). Awards typically vest over multiple years, so they represent future compensation rather than immediate insider buying or selling.
• Derivative award (60,000) carries a staged vesting schedule; until vested, these do not confer immediate marketable shares.